Prof. Dr. Nils Hoppe

Prof. Dr. Nils Hoppe
Otto-Brenner-Str. 1-3
30159 Hannover
Prof. Dr. Nils Hoppe
Otto-Brenner-Str. 1-3
30159 Hannover

Nils Hoppe (CV) is Professor for Ethics and Law in the Life Sciences, Director of the Centre for Ethics and Law in the Life Sciences, and Dean of Research at the Faculty for Humanities and Social Sciences at Leibniz University Hannover.

Nils read laws in Nottingham, Erlangen-Nuremberg and Goettingen with a specialisation in medical law and human rights law. Afterwards he worked in litigation at Browne Jacobson LLP before he became in-house counsel at Goettingen University Hospital. He later took up a position as research fellow in the Department for Ethics and History of Medicine at the University of Goettingen. In 2004 he accepted a position as lecturer at the University of Hannover. In 2007 he became a research fellow both at the Institute for Legal Informatics and at the Center for Philosophy and Ethics of Science at the University of Hannover. He was awarded his PhD in law in Hannover in 2008 with a thesis on the law of equity, and property rights in the life sciences. From 2008 onwards, he coordinated the university’s medical law and bioethics research group before founding the Centre for Ethics and Law in the Life Sciences, of which he is now a director. From 2011 to 2013 Assistant Professor. Appointed full professor for Regulation in the Life Sciences in 2013, and professor for Ethics and Law in the Life Sciences from 2016. From 1 May 2014 member of the UK Biobank Ethics and Governance Council; member of the DFG Senate Committee on Animal Experimentation.

Nils has been an external ethics expert for the European Commission since 2008. From 2008 to 2014, he was an executive board member of the European Association of Health Law and is (since 2010) on the editorial board of the European Journal of Health Law. Nils was a fellow of the Royal Society of Medicine and a member of the RSM’s Open Section Council. He is also a member of The Honourable Society of Gray’s Inn (but has not been called to the bar). In 2010 and 2012, he was a visiting fellow to the Centre for Health, Law and Emerging Technologies at Oxford. Nils was an Associate at the Mason Institute for Medicine, Life Sciences and the Law at the University of Edinburgh and held visiting professorships at the European School of Molecular Medicine, Milan and the University of Vienna‘s Law School.

Nils works as a lawyer for Hill Dickinson LLP and is an associate member at Coram Chambers in London.


  • Honourable Society of Gray's Inn, London, UK
  • Academy for Ethics in Medicine, Goettingen, Germany
  • Society of Legal Scholars, Bristol, UK
  • European Association of Health Law, Edinburgh, UK
  • Royal Society of Medicine, London, UK
  • International Association for Philosophy of Law and Social Philosophy
  • International Bar Association, London, UK,
  • Chartered Institute of Arbitrators, London, UK

Publications (selection)

  • Hoppe N. The Regulation of Biobanking in Germany. In: Slokenberga S, Tzortzatou O, Reichel J, editors. GDPR and Biobanking. Cham: Springer; 2021. p. 277–90 (Law, Governance and Technology Series; vol. 43). doi: 10.1007/978-3-030-49388-2
  • Erikainen S, Friesen P, Rand L, Jongsma K, Dunn M, Sorbie A, ..., Hoppe N et al. Public involvement in the governance of population-level biomedical research: unresolved questions and future directions. J Med Ethics2020. doi: 10.1136/medethics-2020-106530
  • Lanzerath D, Illig T, Bernemann I, Hoppe N, Robienski J. Humanbiobanken. Freiburg im Breisgau: Karl Alber; 2020.
  • Keubler LM, Hoppe N, Potschka H, Talbot SR, Vollmar B, Zechner D et al. Where are we heading? Challenges in evidence-based severity assessment. Lab Ani. 2019. doi: 10.1177/0023677219877216
  • Hoppe N. Die Widerspruchslösung in der Organspende: Warum eine alte Fragestellung ihre Aktualität nicht verliert. Transfusionsmedizin 2018; 8(04):238–41.
  • Hoppe N. The Legal Governance of Animal Biotechnologies. In: Niemann H, Wrenzycki C, editors. Aninmal Biotechnology 2: Emerging breeding technologies. Berlin: Springer; 2018. p. 235–50.
  • Harrison PT, Hoppe N, Martin U. Gene editing and stem cells. J Cyst Fibros. 2018. Jan;17(1):10-16. doi: 10.1016/j.jcf.2017.11.018.
  • Hoppe N. Privacy Laws and Biobanking in Germany. J Law Med Ethics. 2016 Mar;44(1):35-44. doi: 10.1177/1073110516644188. PubMed PMID: 27256122.
  • Kaye J, Briceño Moraia L, Curren L, Bell J, Mitchell C, Soini S, Hoppe N, Øien M, Rial-Sebbag E. Consent for Biobanking: The Legal Frameworks of Countries in the BioSHaRE-EU Project. Biopreserv Biobank. 2016 Jun;14(3):195-200. doi: 10.1089/bio.2015.0123. Epub 2016 May 4. PubMed PMID: 27145287.
  • Briceño Moraia L, Kaye J, Tasse AM, Knoppers BM, Mitchell C, Soini S, Hoppe N, Wallace SE, Øien M. 2015. A comparative analysis of the requirements for the use of data in biobanks based in Finland, Germany, the Netherlands, Norway and the United Kingdom. Medical Law International 14(4): 187-212.
  • Webborn N, Williams A, McNamee M, Bouchard C, Pitsiladis Y, Ahmetov I, Ashley E, Byrne N, Camporesi S, Collins M, Dijkstra P, Eynon N, Fuku N, Garton FC, Hoppe N, Holm S, Kaye J, Klissouras V, Lucia A, Maase K, Moran C, North KN, Pigozzi F, Wang G. Direct-to-consumer genetic testing for predicting sports performance and talent identification: Consensus statement. Br J Sports Med. 2015 Dec;49(23):1486-91. doi: 10.1136/bjsports-2015-095343. PubMed PMID: 26582191; PubMed Central PMCID: PMC4680136.
  • Grewal J, Hoppe N. Don't Forget the Orphans. Eur J Health Law. 2015 Apr;22(2):107-11. PubMed PMID: 26399052.
  • Hoppe N, Rensten K. Mitochondrial Donation. Family Law Week (Online) 17 Feb 2015,
  • Klose J, Klose MA, Metz C, Lehner F, Manns MP, Klempnauer J, Hoppe N, Schrem H, Kaltenborn A. Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era. Langenbecks Arch Surg. 2014 Dec;399(8):1021-9. doi: 10.1007/s00423-014-1214-6. Epub 2014 Jun 4. PubMed PMID: 24888532; PubMed Central PMCID: PMC4232743.
  • Lenk C, Hoppe N. Research governance in placebo-controlled trials. Medical Law International. Vol 14, Issue 3, pp. 115 – 132. First published date: August-27-2014. 10.1177/0968533214547119.
  • Hoppe N, Miola J. Innovation in medicine through degeneration in law? A critical perspective on the Medical Innovation Bill. Medical Law International. Vol 14, Issue 4, pp. 266 – 273. First published date: December-28-2014. 10.1177/0968533214564100.
  • Hoppe N. From omics and etics to policy and ethics: regulating evolution. Front Genet. 2013 Sep 19;4:172. doi: 10.3389/fgene.2013.00172. eCollection 2013. PubMed PMID: 24065981; PubMed Central PMCID: PMC3777015.
  • Metz C, Hoppe N. Organ transplantation in Germany: regulating scandals and scandalous regulation. Eur J Health Law. 2013 Apr;20(2):113-6. PubMed PMID: 23772459.
  • Kaye J, Meslin EM, Knoppers BM, Juengst ET, Deschênes M, Cambon-Thomsen A, Chalmers D, De Vries J, Edwards K, Hoppe N, Kent A, Adebamowo C, Marshall P, Kato K. Research priorities. ELSI 2.0 for genomics and society. Science. 2012 May 11;336(6082):673-4. doi: 10.1126/science.1218015. PubMed PMID: 22582247; PubMed Central PMCID: PMC4151290.
  • Hoppe N, Denoon A. An ethical framework for expanded access to cell-based therapies. Regen Med. 2011 May;6(3):273-5. doi: 10.2217/rme.11.12. PubMed PMID: 21548729.
  • Hoppe N. On the Europeanization of health law. Eur J Health Law. 2010 Sep;17(4):323-8. PubMed PMID: 20873513.